Q-omics provides the consensus-scored MAMDC2 profile across patient tissues and cancer cell-line models. MAMDC2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, MAMDC2 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, MAMDC2 protein abundance shows 31,782 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight LUSC, KIRC, and LUAD as cancer lineages where MAMDC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAMDC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAMDC2 survival associations across molecular data types. MAMDC2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAMDC2 RNA expression–survival associations across cancer types. High MAMDC2 expression shows unfavorable associations in LUSC, BLCA and MESO, but favorable associations in ACC, LIHC and UCS. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for MAMDC2 RNA expression.
This table summarizes MAMDC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MAMDC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAMDC2 shows lower tumor expression in KIRC, COAD, LUAD, BLCA, THCA and LUSC. The KIRC box plot shows higher MAMDC2 RNA expression in normal versus tumor tissue (log2 FC = −1.690, t-test p < 0.001).
This table shows molecular features associated with MAMDC2 in patient tissues and cancer cell lines. In patient samples, MAMDC2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MAMDC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
